Danaher (NYSE:DHR) Given New $260.00 Price Target at Stifel Nicolaus

Danaher (NYSE:DHR) had its price objective boosted by investment analysts at Stifel Nicolaus from $220.00 to $260.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the conglomerate’s stock. Stifel Nicolaus’ target price points to a potential upside of 11.11% from the company’s previous close.

DHR has been the subject of a number of other research reports. UBS Group started coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Danaher in a report on Thursday. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Evercore reiterated an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Finally, Guggenheim boosted their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.68.

Danaher Price Performance

Shares of NYSE DHR opened at $233.99 on Thursday. The firm has a 50-day simple moving average of $215.25 and a 200-day simple moving average of $196.84. The stock has a market capitalization of $164.49 billion, a price-to-earnings ratio of 41.56, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.19. The firm had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm posted $1.89 earnings per share. On average, equities analysts predict that Danaher will post 8.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Gunderson Capital Management LLC acquired a new position in Danaher in the third quarter valued at $765,000. EP Wealth Advisors LLC purchased a new stake in shares of Danaher during the 2nd quarter worth about $3,807,000. Frank Rimerman Advisors LLC grew its holdings in shares of Danaher by 181.9% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock worth $9,051,000 after purchasing an additional 26,363 shares during the period. Birch Hill Investment Advisors LLC increased its position in Danaher by 9.6% during the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock worth $8,984,000 after purchasing an additional 3,553 shares in the last quarter. Finally, Forbes J M & Co. LLP raised its holdings in Danaher by 141.6% in the third quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock valued at $947,000 after buying an additional 2,506 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Revenue rose 8.3% to $6.55 billion, narrowly below or effectively in line with the $6.56 billion estimate. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, signaling confidence that improving customer demand and operating performance will continue. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Biotechnology was a key growth driver: orders increased at a mid-teens rate, while stronger profitability in the segment helped produce the earnings beat. Management also cited improving trends across several end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a potential long-term growth opportunity in drug discovery, describing Danaher as having the foundational technologies—or “building blocks”—to participate in the market. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: The acquisition of Masimo helped offset weaker respiratory diagnostic sales, suggesting integration benefits but also continued softness in parts of the diagnostics portfolio. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
• Negative Sentiment: Revenue did not materially exceed expectations, and the ongoing CEO transition could create uncertainty around execution and Danaher’s strategic priorities despite the stronger outlook. Danaher drops after Q3 revenue miss amid CEO transition

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.